Table 1.

Analysis of changes in tyrosine phosphorylation by mass spectrometry following treatment of SET-2 cells with different JAK inhibitors

P-Tyr siteBSK805 Exp. 1BSK805 Exp. 2CP-690,550 Exp. 1CP-690,550 Exp. 2BBT594
JAK2Y570−1.59−2.80−3.62−2.10−2.68
JAK2Y1007 3.94 6.95 5.34 3.58−0.88
JAK2Y1007, Y1008NDNDNDND−2.16
LYNY266 6.71−0.76 0.25−0.31−2.85
PTPN11Y63 2.50−0.88 0.07 0.30−1.09
PTPN18Y389−1.64−3.40ND−2.13−2.78
PTPN6Y564−2.50−2.65−0.74−0.53−2.37
PTPRAY798−8.64−6.01−0.49 0.11−3.28
SKAP2Y11 3.89−0.27 2.36 1.69−1.83
SKAP2Y197−1.09 0.28 0.26 0.63−0.75
STAT1Y701NDND−3.84ND−3.96
STAT3Y705−2.32−3.67−7.73−2.80 1.37
STAT5AY90−0.98 0.85−0.40 0.49−0.54
STAT5AY694−2.47 0.32−2.60−3.25−2.24
TYK2Y292 4.99−1.32−5.35−0.89 1.94
TYK2Y1054 1.51 1.02 5.18 3.22−4.56

Note: SET-2 cells were treated for 30 minutes with the indicated JAK inhibitors and extracted. Changes in phosphopeptide abundance following JAK inhibitor versus DMSO treatment in the different experiments are displayed as log2 ratios calculated from duplicate runs. The table shows a subset of the detected peptides, and the respective affected phosphotyrosine residues are indicated. ND, Not detected.